Once renal transplant recipients are stabilized and require less frequent follow-up with their transplant team, health care providers outside of the transplant setting play an integral role in patients’ ongoing medical care. Given renal transplant recipients’ inherent complexity, these health care providers often seek consult regarding decisions that may affect transplant-related medications or outcomes. In this review, we discuss answers to 10 of the questions commonly posed to our renal transplant team by other health care providers.
ParasuramanRJulianK; AST Infectious Diseases Community of Practice. Urinary tract infections in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):327-336. doi:10.1111/ajt.12124
4.
FioranteSFernández-RuizMLópez-MedranoFet al. Acute graft pyelonephritis in renal transplant recipients: incidence, risk factors and long-term outcome. Nephrol Dial Transplant. 2011;26:1065-1073. doi:10.1093/ndt/gfq531
5.
GołbiewskaJEDebska-SlizienARutkowskiB.Treated asymptomatic bacteriuria during first year after renal transplantation. Transpl Infect Dis. 2014;16:605-615. doi:10.1111/tid.12255
6.
BodroMSanclementeGLipperheideIet al. Impact of urinary tract infections on short-term kidney graft outcome. Clin Microbiol Infect. 2015;21:1104.e1-e8. doi:10.1016/j.cmi.2015.07.019
7.
Delmas-FrenetteCDoraisMTavares-BrumAet al. Epidemiology and outcome of antimicrobial resistance to gram-negative pathogens in bacteriuric kidney transplant recipients. Transpl Infect Dis. 2017;19:e12722. doi:10.1111/tid.12722
8.
NicolleLEBradleySColganRRiceJCSchaefferAHootonTM.Infectious Diseases Society of America Guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40:643-654.
9.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(suppl 3):S1-S155. doi:10.1111/j.1600-6143.2009.02834.x
10.
GohYSBDengZCheongPSCet al. Screening for asymptomatic bacteriuria at one month after adult kidney transplantation: clinical factors and implications. Clin Transplant. 2017;31:e12954. doi:10.1111/ctr.12954
11.
KotagiriPChembolliDRyanJHughesPDToussaintND.Urinary tract infections in the first year post-kidney transplantation: potential benefits of treating asymptomatic bacteriuria. Transplant Proc. 2017;49:2070-2075. doi:10.1016/j.transproceed.2017.07.008
12.
FioranteSLopez-MedranoFLizasoainMet al. Systematic screening and treatment of asymptomatic bacteriuria in renal transplant recipients. Kidney Int. 2010;78:774-781. doi:10.1038/ki.2010.286
13.
PelléGVimontSLevyPPet al. Acute pyelonephritis represents a risk factor impairing long-term kidney graft function. Am J Transplant. 2007;7:899-907. doi:10.1111/j.1600-6143.2006.01700.x
14.
MoradiMAbbasiMMoradiABoskabadiAJalaliA.Effect of antibiotic therapy on asymptomatic bacteriuria in kidney transplant recipients. Urol J. 2005;2:32-35.
15.
El AmariEBHadayaKBuhlerLet al. Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients. Nephrol Dial Transplant. 2011;26:4109-4114. doi:10.1093/ndt/gfr198
16.
GreenHRahamimovRGoldbergEet al. Consequences of treated versus untreated asymptomatic bacteriuria in the first year following kidney transplantation: retrospective observational study. Eur J Clin Microbiol Infect Dis. 2013;32:127-131. doi:10.1007/s10096-012-1727-2
17.
OrigüenJLópez-MedranoFFernández-RuizMet al. Should asymptomatic bacteriuria be systematically treated in kidney transplant recipients? Results from a randomized controlled trial. Am J Transplant. 2016;16:2943-2953. doi:10.1111/ajt.13829
18.
ArencibiaNAgüeraMLRodeloCet al. Short-term outcome of untreated versus treated asymptomatic bacteriuria in renal transplant patients. Transplant Proc. 2016;48:2941-2943. doi:10.1016/j.transproceed.2016.07.041
19.
OrigüenJFernández-RuizMLópez-MedranoFet al. Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options. Transpl Infect Dis. 2016;18:575-584. doi:10.1111/tid.12547
20.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012;2(5). http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO_BP_GL.pdf. Accessed October 10, 2018.
21.
GlicklichGGordilloRSupeKet al. Angiotensin converting enzyme inhibitor use soon after renal transplantation: a randomized, double-blinded placebo-controlled safety study. Clin Transplant. 2011;25:843-848. doi:10.1111/j.1399-0012.2010.01372.x
22.
OrlicLMikolasevicISladoje-MartinovicBBubicIPavletic-PersicMRackiS.Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the early period after kidney transplantation. Coll Antropol. 2013;3:809-814.
23.
FormicaRNFriedmanALLorberMIBiaMJ.Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period. Transplant Proc. 2004;36:2675-2678. doi:10.1016/j.transproceed.2004.10.013
24.
JenningsDLTaberDJ.Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation. Ann Pharmacother. 2008;42:116-120. doi:10.1345/aph.1K471
25.
RiellaLVGabardiSChandrakerA.Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant. 2012;12:1975-1982. doi:10.1111/j.1600-6143.2012.04084.x
26.
PalmerSCNavaneethanSDCraigJCet al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. 2014;(1):CD005019.
27.
HoldaasHFellströmBColeEet al; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5:2929-2936. doi:10.1111/j.1600-6143.2005.01105.x
28.
WigginsBSSaseenJJPageRLIIet al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134:e468-e495. doi:10.1161/CIR.0000000000000456
29.
NeuvonenPNiemiMBackmanJT.Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565-581. doi:10.1016/j.clpt.2006.09.003
30.
ManciniGBBakerSBergeronJet al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group update (2016). Can J Cardiol. 2016;32(7, suppl):S35-S65. doi:10.1016/j.cjca.2016.01.003
31.
PalepuSPrasadGV.New-onset diabetes mellitus after kidney transplantation: current status and future directions. World J Diabetes. 2015;6:445-455. doi:10.4239/wjd.v6.i3.445
32.
ZinmanBWannerCLachinJMet al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi:10.1056/NEJMoa1504720
33.
NealBPerkovicVMahaffeyKWet al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657. doi:10.1056/NEJMoa1611925
34.
ZaccardiFWebbDRHtikeZZYoussefDKhuntiKDaviesMJ.Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783-794. doi:10.1111/dom.12670
35.
CarlsonCJSantamarinaML.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Expert Opin Drug Saf. 2016;15:1401-1412. doi:10.1080/14740338.2016.1216100
36.
RajasekeranHKimSJCardellaCJet al. Use of canagliflozizin in kidney transplant recipients for the treatment of type 2 diabetes: a case series. Diabetes Care. 2017;40:e75-e76. doi:10.2337/dc17-0237
37.
Tacrolimus and ciprofloxacin [package insert]. Hudson, OH: Lexi-Comp Inc; 2017.
38.
WoosleyRLHeiseCWRomeroKA.QTdrugs List. Oro Valley, AZ: AZCERT Inc; 2013.
39.
MaruyamaMLiBYChenHet al. FKBP12 is a critical regulator of the heart rhythm and the cardiac voltage-gated sodium current in mice. Circ Res. 2011;108:1042-1052. doi:10.1161/CIRCRESAHA.110.237867
40.
JohnsonMCSoSMarshJWMurphyAM.QT prolongation and torsades de pointes after administration of FK506. Transplantation. 1992;53:929-930.
41.
HodakSMoubarakJBRodriquezIGelfandMCAlijaniMRTracyCM.QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplantation. 1998;66:535-537.
42.
AkersWSFlynnJDDavisGAGreenAEWinsteadSStrobelG.Prolonged cardiac repolarization after tacrolimus and haloperidol administration in the critically ill patient. Pharmacotherapy. 2004;24:404-408.
43.
van der SijsHKowlesarRKlootwijkPJNewlanSPVultoAGvan GelderT.Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67:347-354. doi:10.1111/j.1365-2125.2008.03357.x
44.
BurgerCIClaseCMGangjiAS.Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. Transplantation. 2010;89:1166-1167. doi:10.1097/TP.0b013e3181d2fed7
45.
IkitimurBCosansuKKaradagBet al. Long-term impact of different immunosuppressive drugs on QT and PR intervals in renal transplant patients. Ann Noninvasive Electrocardiol. 2015;20:426-432. doi:10.1111/anec.12225
46.
KangJWangLChenXLTriggleDJRampeD.Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001;59:122-126.
47.
BriasoulisAAgarwalVPierceWJ.QT prolongation and torsades de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology. 2011;120:103-110. doi:10.1159/000334441
48.
InghammarMSvanströmHMelbyeMPasternakBHviidA.Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. BMJ. 2016;352:i843. doi:10.1136/bmj.i843
49.
TugcuM.Increased tacrolimus levels after administration of ciprofloxacin to a patient with renal transplant. Turk Nephrol Dial Transplant. 2016;25(suppl 1):171-174. doi:10.5262/tndt.2016.42
50.
UlrichCKanitakisJStockflethEEuvrardS.Skin cancer in organ transplant recipients—where do we stand today?Am J Transplant. 2008;8:2192-2198. doi:10.1111/j.1600-6143.2008.02386.x
51.
SzepietowskiJCReichANowickaDWeglowskaJSzepietowskiT.Sun protection in renal transplant recipients: urgent need for education. Dermatology. 2005;211:93-97. doi:10.1159/000086435
52.
Imko-WalczukBGraczykMKorbanMKielbowiczMDebska-SlizienARutkowskiB.Impact of skin cancer awareness on prophylactic behavior among renal transplant recipients. Transplant Proc. 2016;48:1526-1531. doi:10.1016/j.transproceed.2015.11.040
53.
MoloneyFJAlmarzouqiEO’KellyPConlonPMurphyGM.Sunscreen use before and after transplantation and assessment of risk factors associated with skin cancer development in renal transplant recipients. Arch Dermatol. 2005;141:978-982.
54.
GordonLGScuffhamPAvan der PolsJCMcBridePWilliamsGMGreenAC.Regular sunscreen use is a cost-effective approach to skin cancer prevention in subtropical settings. J Invest Dermatol. 2009;129:2766-2771. doi:10.1038/jid.2009.141
HirstNGGordonLGScuffhamPAGreenAC.Life cost-effectiveness of skin cancer prevention through promotion of daily sunscreen use. Value Health. 2012;15:261-268. doi:10.1016/j.jval.2011.10.009
KimGKDel RossoJQ.The risk of fluoroquinolone-induced tendinopathy and tendon rupture: what does the clinician need to know?J Clin Aesthet Dermatol. 2010;3:49-54.
van der LindenPDSturkenboomMCHeringsRMLeufkensHMRowlandsSStrickerBH.Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med. 2003;163:1801-1807.
63.
van der LindenPDvan de LeiJNabHWKnolAStrickerBH.Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol. 1999;49:433-437. doi:10.1046/j.1365-2125.1999.00016.x
64.
ParmarCMedaKP.Achilles tendon rupture associated with combination therapy of levofloxacin and steroid in four patients and a review of the literature. Foot Ankle Int. 2007;28:1287-1289. doi:10.3113/FAI.2007.1287
65.
van der LindenPDSturkenboomMCHeringsRMLeufkensHGStrickerBH.Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ. 2002;342:1306-1307.
66.
WiseBPeloquinCChoiHLaneNZhangY.Impact of age, sex, obesity, and steroid use in quinolone-associated tendon disorders. Am J Med. 2012;125:1228.e23-1228.e28. doi:10.1016/j.amjmed.2012.05.027
67.
HumbyrdCJBaeSKucirkaLMSegevDL.Incidence, risk factors, and treatment of Achilles tendon rupture in patients with end-stage renal disease. Foot Ankle Int. 2018;39:821-828. doi:10.1177/1071100718762089
68.
KhaliqYZhanelGC.Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36:1404-1410.
69.
WangLVerschuurenEAvan Leer-ButerCCet al. Herpes zoster and immunogenicity and safety of zoster vaccines in transplant recipients: a narrative review of the literature. Front Immunol. 2018;9:1632. doi:10.3389/fimmu.2018.01632
70.
PergamSALimayeAP; AST Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):138-146. doi:10.1111/ajt.12107
71.
FashnerJBellAL.Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician. 2011;83:1432-1437.
72.
LeeIBlumbergA. Risk and epidemiology of infections after solid organ transplantation. In: LjungmanPSnydmanDBoeckhM, eds. Transplant Infections. 4th ed.Basel, Switzerland: Springer; 2016:101-112.
RubinLGLevinMJLjungmanPet al; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44-e100. doi:10.1093/cid/cit684
ChongPPAveryRK.A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients. Clin Ther. 2017;39:1581-1598. doi:10.1016/j.clinthera.2017.07.005
77.
CroceEHatzCJonkerEFVisserLGJaegerVKBühlerS.Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation—a systematic review of randomized trials, observational studies and case reports. Vaccine. 2017;35:1216-1226. doi:10.1016/j.vaccine.2017.01.048
78.
VinkP.Immunogenicity and safety of a candidate subunit adjuvanated herpes zoster vaccine (HZ/su) in adults post renal transplant: a phase III randomized clinical trial. Open Forum Infect Dis. 2017;4(suppl 1):S417. doi:10.1093/ofid/ofx163.1044
79.
StadtmauerEASullivanKMMartyFMet al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124:2921-2929. doi:10.1182/blood-2014-04-573048
80.
BerkowitzEMMoyleGStellbrinkHJet al; Zoster-015 HZ/su Study Group. Safety and immunogenicity of an adjuvanated herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211:1279-1287. doi:10.1093/infdis/jiu606
DendleCStuartRLMulleyWRHoldsworthSR.Pneumococcal vaccination in adult solid organ transplant recipients: a review of current evidence. Vaccine. 2018;36:6253-6261. doi:10.1016/j.vaccine.2018.08.069
84.
DobbelsFSkeansMASnyderJJTuomariAVMacleanJRKasiskeBL.Depressive disorder in renal transplantation: an analysis of Medicare claims. Am J Kidney Dis. 2008;51:819-828. doi:10.1053/j.ajkd.2008.01.010
85.
NovakMMolnarMZSzeifertLet al. Depressive symptoms and mortality in patients after kidney transplantation: a prospective prevalent cohort study. Psychosom Med. 2010;72:527-534. doi:10.1097/PSY.0b013e3181dbbb7d
86.
CukorDRosenthalDJindalRMBrownCDKimmelPL.Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients. Kidney Int. 2009;75:1223-1229. doi:10.1038/ki.2009.51
87.
DiMatteoMRLepperHSCroghanTW.Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-2107.
88.
DewMRosenbergerEMMyaskovskyLet al. Depression and anxiety as risk factors for morbidity and mortality after organ transplantation: a systematic review and meta-analysis. Transplantation. 2015;100:988-1003. doi:10.1097/TP.0000000000000901
89.
ChristiansUSchmitzVHaschkeM.Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol. 2005;1:641-654.
90.
SpinaEPisaniFde LeonJ.Clinically significant pharmacokinetic interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016;106:72-86. doi:10.1016/j.phrs.2016.02.014
91.
KimJPhongsamranPParkS.Use of antidepressant drugs in transplant recipients. Prog Transplant. 2004;14:98-104.
92.
CroneCCGabrielGM.Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2004;43:361-394.
93.
VellaJPSayeghMH.Interactions between cyclosporine and newer antidepressant medications. Am J Kidney Dis. 1998;31:320-323.
94.
MarkowitzJSGillHSHuntNMMonroeRRJrDeVaneCL.Lack of antidepressant-cyclosporine pharmacokinetic interactions. J Clin Psychopharmacol. 1998;18:91-93.
95.
ListonHLMarkowitzJSHuntNDeVaneCLBoultonDWAshcraftE.Lack of citalopram effect on the pharmacokinetics of cyclosporine. Psychosomatics. 2001;42:370-372.
96.
StrouseTBFairbanksLASkotzkoCEFawzyFI.Fluoxetine and cyclosporine in organ transplantation: failure to detect significant interactions or adverse clinical events in depressed organ recipients. Psychosomatics. 1996;37:23-30.
97.
CampoJVSmithCPerelJM.Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent. Arch Gen Psychiatry. 1998;55:1050-1052.
98.
LewisBRAounSLBernsteinGACrowSJ.Pharmacokinetic interactions between cyclosporine and bupropion or methylphenidate. J Child Adolesc Psychopharmacol. 2001;11:193-198.
FunkKABostwickJR.A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013;47:1330-1341. doi:10.1177/1060028013501994
101.
NeweyCRKhawamECoffmanK.Two cases of serotonin syndrome with venlafaxine and calcineurin inhibitors. Psychosomatics. 2011;52:286-290. doi:10.1016/j.psym.2010.12.007
102.
WongEHChangNNSzeKHOrKH.Serotonin syndrome in a renal transplant patient. J R Soc Med. 2002;95:304-305.
103.
ErnstE.St John’s Wort supplements endanger the success of organ transplantation. Arch Surg. 2002;137:316-319.
